Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised …

N Sattar, MMY Lee, SL Kristensen… - The lancet Diabetes & …, 2021 - thelancet.com
Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …

[HTML][HTML] GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art

MA Nauck, DR Quast, J Wefers, JJ Meier - Molecular metabolism, 2021 - Elsevier
Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

[HTML][HTML] Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes

HC Gerstein, N Sattar, J Rosenstock… - New England journal …, 2021 - Mass Medical Soc
Background Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally
similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular …

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 …

HJL Heerspink, N Sattar, I Pavo, A Haupt… - The Lancet Diabetes & …, 2022 - thelancet.com
Background In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide
reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily …

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular …

SL Kristensen, R Rørth, PS Jhund… - The lancet Diabetes & …, 2019 - thelancet.com
Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their
structure and duration of action and have been studied in trials of varying sizes and with …

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

HC Gerstein, HM Colhoun, GR Dagenais, R Diaz… - The Lancet, 2019 - thelancet.com
Background Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce
cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high …

Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1

R Hammoud, DJ Drucker - Nature Reviews Endocrinology, 2023 - nature.com
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …

[HTML][HTML] KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease

IH de Boer, ML Caramori, JCN Chan… - Kidney …, 2020 - kidney-international.org
This is an opportune time to publish the first KDIGO 2020 Clinical Practice Guideline for
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …

Treatment of type 2 diabetes: challenges, hopes, and anticipated successes

MA Nauck, J Wefers, JJ Meier - The Lancet Diabetes & …, 2021 - thelancet.com
Despite the successful development of new therapies for the treatment of type 2 diabetes,
such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose …

Innate immunity in diabetic kidney disease

SCW Tang, WH Yiu - Nature Reviews Nephrology, 2020 - nature.com
Increasing evidence suggests that renal inflammation contributes to the pathogenesis and
progression of diabetic kidney disease (DKD) and that anti-inflammatory therapies might …